



ASX ANNOUNCEMENT

15 January 2026

Vitrafy Life Sciences – IMV Strategic Commercial Agreement Briefing

Vitrafy Life Sciences Limited (ASX: VFY), (**Vitrafy** or **Company**) will provide investors a briefing on the announced Strategic Commercial Agreement with IMV Technologies.

Vitrafy will host an investor briefing at **9:30AM (AEDT)** on **Thursday 15 January 2026** to provide a briefing on the Agreement and answer questions from investors.

The Company invites investors to join the briefing. To attend, please register via the following link:
https://us06web.zoom.us/webinar/register/WN_eQet6ewpRZu9ZjXDbZcl5g

After registering, you will receive a confirmation email containing information on how to join the briefing.

Investors are encouraged to submit any questions in advance to Vitrafy's Investor Relations using the contact details below.

ENDS

This announcement is authorised by the Company Secretary of Vitrafy Life Sciences Limited.

For further information contact:

Investor and Media Relations

Simon Martin

Chief Financial Officer

investors@vitrafy.com

About Vitrafy Life Sciences Limited

Vitrafy Life Sciences Limited (ASX: VFY) has developed breakthrough cryopreservation technology that dramatically improves cell survival rates across multiple applications including blood platelets (>88% recovery vs >50% industry standard), cell & gene therapies (96% viability vs 70% industry minimum), aquaculture and bovine reproduction. The Company provides complete cryopreservation solutions through its managed service revenue model, utilising its FDA-registered Smart Freezing and Smart Thawing devices, integrated LifeChain™ software platform, and Smart Packaging systems.

For more information visit vitrafy.com.